These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31114280)

  • 1. Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus.
    Xie J; Li N; Jiang X; Chai L; Chen JJ; Deng W
    Diabetes Metab Syndr Obes; 2019; 12():519-526. PubMed ID: 31114280
    [No Abstract]   [Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
    Kumar S
    Indian J Endocrinol Metab; 2021; 25(4):326-331. PubMed ID: 35136740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.
    Wang SL; Dong WB; Dong XL; Zhu WM; Wang FF; Han F; Yan X
    Oncotarget; 2017 Sep; 8(42):72700-72713. PubMed ID: 29069819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
    Terawaki Y; Iwaya C; Nomiyama T; Shimono D; Horikawa T; Fujimura-Tanaka Y; Shigeoka T; Hamanoue N; Motonaga R; Tanabe M; Yanase T; Kawanami D;
    Diabetol Int; 2020 Jul; 11(3):274-282. PubMed ID: 32802709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials.
    Zhu H; Zhu S; Zhang X; Guo Y; Shi Y; Chen Z; Leung SW
    Diabetol Metab Syndr; 2013 Nov; 5(1):70. PubMed ID: 24228743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus.
    Tandon T; Dubey AK; Srivastava S; Manocha S; Arora E; Hasan N
    J Family Med Prim Care; 2019 Mar; 8(3):955-959. PubMed ID: 31041232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.
    Jeon HJ; Oh TK
    Diabetes Metab J; 2011 Oct; 35(5):529-35. PubMed ID: 22111045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
    Peng Y; Chen SH; Liu XN; Sun QY
    J Cell Physiol; 2019 Mar; 234(3):2795-2806. PubMed ID: 30145806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
    González-Ortiz M; Martínez-Abundis E;
    Rev Invest Clin; 2004; 56(3):327-33. PubMed ID: 15612515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus.
    Kawamori R; Kaku K; Hanafusa T; Oikawa T; Kageyama S; Hotta N
    J Diabetes Investig; 2014 Feb; 5(1):72-9. PubMed ID: 24843740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study.
    Du G; Xie W; Su Y; Ma Y; Gao X; Jiang S; Liang H
    PeerJ; 2020; 8():e9905. PubMed ID: 33072435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
    Fang FS; Gong YP; Li CL; Li J; Tian H; Huang W; Wang LC; Li L
    Eur J Endocrinol; 2014 Jun; 170(6):901-8. PubMed ID: 24694876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J
    Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.